Zydus Cadila has launched a biosimilar of Adalimumab, which is used in the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis and Ankylosing Spondylitis.

Though the innovator drug is currently still under patent in the US, it is not sold in India. The US patent is expected to expire in 2019, though it will lose patent in other markets earlier.

Zydus Cadila expects to garner Rs 100 crore in revenues from this product in three years.

According to the company senior officials, the drug would cost about a fifth in India compared to the US, where it is priced at about $1,000 a vial.